Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.64 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23088623 | 1.00 | PDE4D (0.64) | PDE4DPDE10AMAPK1AOC3EHMT2 | |
| SCHEMBL23088624 | 1.00 | PDE4D (0.64) | PDE4DPDE10AMAPK1AOC3EHMT2 | |
| SCHEMBL23088621 | 0.91 | PDE4D (0.62) | PDE4DPDE10AMAPK1EHMT2EHMT1 | |
| SCHEMBL30712004 | 0.91 | PDE4D (0.62) | PDE4DPDE10AMAPK1EHMT2EHMT1 | |
| SCHEMBL23088619 | 0.91 | PDE4D (0.62) | PDE4DPDE10AMAPK1EHMT2EHMT1 | |
| SCHEMBL30712006 | 0.87 | PDE4D (0.65) | PDE4DPDE10AEHMT2EHMT1MAPK14 | |
| SCHEMBL23088646 | 0.87 | PDE4D (0.65) | PDE4DPDE10AEHMT2EHMT1MAPK14 | |
| SCHEMBL23088644 | 0.87 | PDE4D (0.65) | PDE4DPDE10AEHMT2EHMT1MAPK14 | |
| SCHEMBL23088641 | 0.81 | PDE4D (0.45) | PDE4DKMT2A | |
| SCHEMBL23088651 | 0.81 | PDE4D (0.45) | PDE4DKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111727191-B | Substituted azetidine dihydro-thienopyridines and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-01-05 | — | — | CN | claimed |
| US-20240400578-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2024-12-05 | — | — | US | disclosed |
| CN-111727191-B | Substituted azetidine dihydro-thienopyridines and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-01-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400578-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE3A, PDE3B | PDE4D 12/4885PDE10A 21/4885MAPK1 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.